Background: Although reports have described the perceptions of curability among patients with unresectable/recurrent cancer and the quality of death and dying, the association between patients' perceptions and physicians' disclosures of incurability remained unexplored. This survey aimed to evaluate the association between patients' perceptions of curability and physicians' disclosures of incurability. Methods: In this cross-sectional, multicenter, observational study in Japan, we asked outpatients with unresectable/recurrent solid cancers about their perceptions of incurability. The patient inclusion criteria were unresectable/recurrent solid cancer, failure of first-line chemotherapy and an age ≥ 20 years. Additionally, we surveyed their primary responsible physicians regarding disclosures to patients regarding incurability. Results: Although we estimated the necessary sample size as 250, we discontinued recruitment because the responsible researcher transferred to another hospital. Among the 135 included and surveyed patients, 39% responded that their cancer was incurable, 33% responded that their cancer was curable and 23% responded 'I don't know' or 'I don't wish to answer'. No significant association was observed between patients' perceptions of curability and physician-reported disclosures of incurability. Conclusion: In this Japanese population, 39% of patients with unresectable/recurrent solid cancers perceived that their cancers were incurable. However, such perceptions did not appear to be significantly affected by physician-reported disclosures. We recommend additional research
Introduction
It is important to understand the perceptions of disease incurability among patients with unresectable/recurrent solid cancers, as this factor affects the quality of death and dying. In the Cancer Care Outcome Research and Surveillance (CanCORS) study of patients with metastatic cancer in the United States (US), patients who perceived that their cancers were incurable were significantly more likely to participate in hospice programs, compared with those who believed that their diseases could be cured (1) . Notably, participation in a hospice program indicates that a terminal cancer patient will receive a high quality of care (2, 3) , and such programs have been associated with the quality of end-of-life care and quality of life of terminal cancer patients (4) (5) (6) .
In contrast, end-of-life discussions with physicians are also important. Wright et al. (5) described that patients who discussed end-of-life issues with their physician significantly tended to accept their terminal illness and more likely used outpatient hospice services over 1 week. Similarly, Mack et al. (7) reported that patients who discussed using life-sustaining machines or receiving hospice care with their physicians significantly tended to receive less aggressive end-of-life care, such as chemotherapy, in the last 14 days of life or intensive care unit addition in the last 30 days and more likely received hospice care. Hence, how physicians discuss end-of-life issues with patients may play an important role in providing highquality care for patients' end of life.
However, patients with unresectable/recurrent cancers tend to have excessively optimistic perceptions regarding their diseases. In a study by Wright et al. (5) from the US, only 37.5% of patients with metastatic cancer believed their disease was incurable. Similarly, Weeks et al. (8) reported that only 31% of patients with metastatic lung cancer and 19% of patients with colorectal cancer correctly responded that chemotherapy offered no curative potential. In other words, the perceptions held by most patients with unresectable/ recurrent cancer regarding curability might not align with reality.
Several factors concerning perceptions of curability have been reported. A report by Fisher et al. (9) described patient factors such as the place of residence, prognosis, cognitive function, activities of daily living, depression, suicidal thoughts, loss of appetite, mental stability and respiratory distress. Similarly, Tang et al. (10) reported age, sex, educational background and type of cancer as relevant patient factors. Notably, all identified pertinent factors were patient-focused and previous studies have failed to evaluate physicians' disclosures of incurability to their patients, particularly the means by which the primary responsible physicians explained curability and/or prognosis. Therefore, this study aimed to examine the association between patients' perceptions of curability and physician-reported disclosures of incurability.
Materials and methods

Study design
This cross-sectional, multicenter, observational survey included consecutive outpatients with unresectable/recurrent solid cancers who were treated between February 2015 and January 2016 at Tohoku University Hospital and Miyagi Cancer Center. These tertiary hospitals include cancer centers certified by the Japanese Ministry of Health, Labor and Welfare. Researchers screened the medical records of participating hospitals and identified eligible patients. The institutional review boards of all participating institutions approved the study protocol.
Written informed consent was obtained from all participants, who were asked to complete and send survey questionnaires to our office. Concurrently, we screened participants' cognitive functions using the Mini-Cog test, a cognitive test (11, 12) validated by the Mini Mental State Examination. During this test, participants memorized three words, followed by a clock-drawing test after which they were asked to recall the three words. We defined a positive test result as a failure to recall three words or failure to recall more than one word as well as a mistake in the clock-drawing test (13) .
We defined the primary responsible physician as the doctor who had most frequently examined the patient and was responsible for both treatment and informed consent. We identified these individuals through a search of patients' medical records. After obtaining informed consent, each primary responsible physician was immediately asked about the explanations provided to their patients.
Patient survey
In this study, the inclusion criteria were unresectable/recurrent solid cancer, failure of first-line chemotherapy and age ≥ 20 years. Patients were excluded if they declined to provide written informed consent, received a positive Mini-Cog test result, had no imageconfirmed lesion, had not been informed about their disease, could not understand the Japanese questionnaire, did not have sufficient stamina to complete the questionnaire or were deemed ineligible by the primary responsible physician. All these exclusion criteria were determined by a primary responsible physician or medical records.
Based on a reference point established prior to the study (1, 7, 8) , we asked patients about their perceptions of curability using the question: 'How likely do you think that the chemotherapy you are currently receiving will be able to completely cure your cancer?' The response options were 'It is highly possible', 'Somewhat possible', 'Slightly possible', 'Not possible', 'I don't know' and 'I don't wish to answer'. These questions, which were used in three prospective longitudinal studies in the US (7, 14, 15) , were used in this study after receiving Japanese validation via the back-translation method. Briefly, the principal investigator and colleagues examined the validity of the professionally translated Japanese statements. Subsequently, the revised translations were sent back to the translator for retranslation into English. Finally, we confirmed the uniformity of the questions with two authors of the three prior papers (7, 14, 15) . In addition, we asked patients 'How would you describe your current health condition?' with response options of 'Good. There is hope that I will recover', 'I am in serious condition, but there is hope that I will recover', 'Serious. There is no hope that I will recover', 'I don't know' and 'I don't wish to answer' with reference to a prior study (14) . Patients who described themselves as 'Good. There is hope that I will recover' and 'I am in serious condition, but there is hope that I will recover' were considered to have no awareness of their terminal illness, and patients who described themselves as 'Serious. There is no hope that I will recover' were considered to have awareness of their terminal illness. We also asked patients how their primary responsible physician explained the purpose of chemotherapy with reference to a prior study (15) . We asked patients 'How did your physician explain the goal of the chemotherapy that you are currently undergoing to you?' with response options of 'To cure the cancer', 'The treatment will not be able to completely cure the cancer, but it will extend my life', 'The treatment will reduce my cancer-related symptoms', and 'Other'. We used similar backtranslation methods for these two questions. Detailed questions and response options are shown in the Supplemental data.
In addition to survey data, we obtained patient characteristics, including age, sex, type of cancer, name of the primary responsible physician and number of chemotherapy regimens, from the medical records. We inquired about each patient's educational level, marital status and family income via questionnaire. Furthermore, we solicited the patients' Eastern Cooperative Oncology Group performance statuses (ECOG PS) from the primary responsible physicians.
Physician survey
Primary responsible physicians were asked whether they had disclosed information about the following to their patients: purpose of chemotherapy, prognosis, health status, palliative care after discontinuation of chemotherapy, preferred place of death and do not attempt resuscitation (DNAR) orders. The validity of all questions and response options were checked by all authors, including specialists of medical oncology, palliative care and palliative nursing. Detail questions and response options are shown in the Supplemental data. Primary responsible physicians answered these questions immediately after patient registration.
Sample size
We estimated the necessary sample size using the standard error, given the lack of similar studies in Japan. Based on the figure of 19% reported by Weeks et al. (8), we estimated that 20% of patients would respond that their cancers were incurable. Therefore, 246 patients would be required to yield a standard error <0.05 and the target sample was set at 250 patients.
Statistical analysis
The descriptive analysis performed in this study included patient characteristics such as age, sex, ECOG PS, education, marital status, income, cancer type and number of chemotherapy regimens. Additionally, we summarized the reported perceptions of curability according to sociodemographic and clinical factors. After excluding answers such as 'I don't know' or 'I don't wish to answer' and missing answers, we classified patients' perceptions as curable (answers: 'It is highly possible', 'Somewhat possible' and 'Slightly possible') or incurable (answer: 'Not possible'). Associations between continuous, ordinal and categorical variables were determined using the Wilcoxon rank-sum test, Cochran-Armitage trend test and Fisher's exact test, respectively. SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses. A two-sided P value of <0.05 was considered statistically significant.
Results
Patient characteristics
Of the 178 eligible patients, 148 enrolled in the study (consent rate = 82.6%). The most common reason for exclusion was a refusal to participate (n = 11, 35.5%), followed by inability to participate (n = 9, 29.0%) and cognitive impairment (n = 5, 16.7%). Eligible and excluded patients did not differ significantly regarding characteristics such as age, sex or type of cancer (Supplementary data, Table 1 ). In addition, 13 of 148 patients did not return their questionnaires. Accordingly, our final analysis included 135 patients (survey completion rate = 91.2%). The characteristics of these patients are shown in Table 1 . During study recruitment, the responsible researcher was transferred to another hospital, and our inability to recruit additional participants limited our study sample size considerably relative to the target of 250.
Physician characteristics
Sixteen primary responsible physicians participated in the physician survey, with medical oncology as the background of all physicians. They primarily attended to patients with solid cancer, including gastrointestinal, hepatobiliary, lung, head and neck, breast and sarcoma.
Patient perceptions of curability
Among the 135 eligible patients, 53 (39%) perceived that their cancer was incurable, whereas 45 (33%) perceived that their cancer was curable. Another 31 patients (23%) responded with 'I don't know' or 'I don't wish to answer' and 6 (4%) did not answer the question. We conducted a univariate analysis to compare characteristics between patients stratified by perceptions of curability (Table 2) . We identified that older, male patients tend to misunderstand whether their cancer is curable but did not identify any other significant inter-group differences.
Association between patient's perception of curability and patients answers
Patients who considered their health status as terminal significantly tended to perceive that their cancer was not curable (Table 3) . However, no significant association was observed between patient perception of curability and patient-perceived disclosure of the purpose of chemotherapy.
Association between patient's perception of curability and physician-reported disclosure
The purpose of chemotherapy as being not to explicitly or indistinctly cure was disclosed in 93 patients (95%) ( Table 4 ). The purpose of chemotherapy was not disclosed in three patients. Prognosis (68%), palliative care after discontinuation of chemotherapy (56%), preferred place of death (83%) and DNAR order (96%) were not disclosed in over half of the patients. Almost all physicians disclosed patient's health status as serious and that their cancer was incurable. Our analysis did not reveal any significant associations of physician-reported disclosures, including the purpose of chemotherapy, prognosis, health status, palliative care after discontinuation of chemotherapy, preferred place of death and DNAR orders, with patients' perceptions of curability.
Discussion
This study of Japanese patients with unresectable/recurrent solid cancers yielded two major findings. First, fewer than 40% of the patients understood that their diseases were incurable. Second, physician's disclosures of incurability did not significantly associate with patients' perceptions of curability.
Previous studies of patient perception reported age (9,16), education (9,16), sex (9) and type of cancer (9) as associated factors; however, these are patient-centered factors. Therefore, we chose to conduct a detailed investigation of physician-reported disclosures. In our univariate analysis, although patients whose primary responsible physicians disclosed the incurable nature of the disease tended to answer that their cancers were incurable, all disclosures by their primary responsible physician were not significantly associated with patients' perceptions. Our findings, when combined with those of previous studies (9, 16) , suggest that patient factors, rather than physicians' disclosures, might play a more important role in patients' perceptions of curability. In a patient survey, Weeks et al. (8) observed that those who attributed lower scores to physician communication were more likely to recognize their incurable status. The authors attributed this finding to the potential perception of physicians who presented a more optimistic view of chemotherapy as better communicators. However, in the present study, almost all primary responsible physicians had directly disclosed their patients' incurable statuses (Table 3) , and therefore our results do not support the explanation by Weeks and colleagues. We note, however, that patient-related factors might have confounded our results and recommend future studies to elucidate the association between physician communication and patients' perceptions of curability.
Although we estimated that approximately 20% of patients would answer that their cancer was incurable based on the 19% reported by Weeks et al. (8) , 39% of our patients recognized their incurable illness. This discrepancy may occur because patients who are aware of their terminal illness significantly tend to recognize their incurability (Table 3) . Moreover, a majority of patients (87%) responded that their primary responsible physician disclosed that the purpose of chemotherapy was for prolonging life or palliation (Table 3) . Hence, patients appeared to recognize their incurability and understand their physician's disclosure correctly. This discrepancy regarding patients' perception of incurability may not be because of collusion between patients and physicians but because of patients' denial coping. In addition, the type of cancer may contribute to the result. Weeks et al. (8) further reported that 19 and 31% of patients with colorectal and lung cancer, respectively, recognized their incurability, and patients with colorectal cancer significantly tend to misunderstand their incurability compared with those with lung cancer (odds ratio, 1.75; 95% confidence interval, 1.29-2.37). The participants of our survey included many patients with cancer, such as esophageal, gastric, lung and pancreatic cancer, with poor prognosis. Furthermore, the rate of ambiguous answers, such as 'I don't know' or 'I don't wish to answer' was high (23%), which may contribute to this result. Some patients may have hoped that their cancer was curable but answered 'I don't know' because of anxiety or denial coping. Premature cessation of patient recruitment may also influence the data variance.
Our study had several strengths, including a high survey completion rate (>90%). In addition, eligible patients were recruited consecutively, thus allowing us to obtain data in a more realistic setting. Moreover, although cancer patients tend to have a poor health status and high risk of depression, only 14 (7.9%) patients were excluded from this study because of physicians' determinations of bad health status or depression, indicating limited selection bias.
Despite these strengths, several limitations should be considered when interpreting the results. First, the statistical power was weaker than planned because we terminated the survey before reaching our target number of patients. Hence, patient perception of cancer incurability may have affected this limitation. Second, this study was Patients who completed the first-line chemotherapy and stopped any chemotherapy. Patients who completed the first-line chemotherapy and stopped any chemotherapy. conducted in a limited region in Japan, and our results may not be generalizable to other regions of Japan or countries. Third, the cross-sectional design did not allow us to suggest causality between patients' perceptions of curability and other factors. Fourth, a high percentage of physician answers that they disclosed incurability to their patients may be affected by social desirability bias. Finally, recall bias might be present, as we asked patients and doctors about previous discussions. Still, our results include some important suggestions for clinical practice, i.e. there are some differences between patients understanding their incurability and accepting it. Hence, we cannot presume that patients will accept physicians' disclosures emotionally, even when important information is provided in detail. In our study, 34 patients (35%) answered 'I don't know' or I don't wish to answer' when queried about their health status. These ambiguous answers may be attributed to denial coping. In addition, collusion between patients and physicians may play a role in difficulty of end-of-life discussion, such as palliative care after discontinuation of chemotherapy, preferred place of death and DNAR status. Keating et al. (17) reported that almost 70% of physicians would not discuss hospice enrollment and DNAR status until symptoms emerged or no treatment options were available. In addition, Weeks et al. (8) suggested that collusion may exist between patients with cancer and their physicians. Future research should focus on the coping patterns of patients and the status of collusion between patients and their physicians. Further study is required to explore end-of-life discussion tactics that would allow cancer patients to form realistic perceptions of their situations. 
Conclusion
In our survey of patients with unresectable/recurrent solid cancers, only 39% recognized their incurability. We further observed that physicians' disclosures did not affect the patients' perceptions, as the primary responsible physicians had disclosed the purpose of chemotherapy to most patients who believed their cancers to be curable. Our findings suggest that additional research is needed to identify the coping pattern of patients, status of collusion between patients and their physicians, and methods of disclosure that would best allow patients to understand incurability.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
